Mechanisms of apoptosis in irradiated and sunitinib-treated follicular thyroid cancer cells

被引:40
作者
Grosse, Jirka [1 ]
Warnke, Elisabeth [2 ]
Wehland, Markus [2 ]
Pietsch, Jessica [2 ]
Pohl, Fabian [3 ]
Wise, Petra [4 ]
Magnusson, Nils E. [5 ,6 ]
Eilles, Christoph [1 ]
Grimm, Daniela [2 ,6 ]
机构
[1] Univ Regensburg, Dept Nucl Med, D-93053 Regensburg, Germany
[2] Univ Magdeburg, Clin Plast Aesthet & Hand Surg, D-39106 Magdeburg, Germany
[3] Univ Regensburg, Dept Radiooncol, D-93053 Regensburg, Germany
[4] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90033 USA
[5] Univ Aarhus, Fac Hlth Sci, Dept Clin Med, Med Res Labs, Aarhus, Denmark
[6] Aarhus Univ, Inst Biomed, DK-8000 Aarhus C, Denmark
关键词
Thyroid cancer; Sunitinib; Irradiation; Apoptosis; Survivin; Caspases; BREAST-CANCER; THERAPEUTIC TARGET; ENDOTHELIAL-CELLS; PARABOLIC FLIGHT; KINASE INHIBITOR; BCL-2; FAMILY; SURVIVIN; CARCINOMA; DEATH; GENE;
D O I
10.1007/s10495-013-0937-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The multikinase inhibitor sunitinib (S) seems to have promising potential in the treatment of thyroid cancer. We focused on the impact of S and/or irradiation (R) on mechanisms of apoptosis in follicular thyroid cancer cells. The effects of R, S and their combination were evaluated 2 and 4 days after treatment, using the human thyroid cancer cell line CGTH W-1. The transcription of genes involved in the regulation of apoptosis was investigated using quantitative real-time PCR. Western blot analyses of caspases and survivin were also performed. S elevated BAX (day 4), CASP9, CASP3, BIRC5 (day 4) and PRKACA (day 4) gene expression, whereas the mRNAs of BCL2, CASP8, PRKCA, ERK1, and ERK2 were not significantly changed. S, R and R+S clearly induced caspase-9 protein and elevated caspase-3 activity. Survivin was down-regulated at day 4 in control cells and the expression was blunted by S treatment. R+S induced survivin expression at day 2 followed by a reduction at day 4 of treatment. Sunitinib and the combined application with radiation induced apoptosis in follicular thyroid cancer cells via the intrinsic pathway of apoptosis. In addition, sunitinib might induce apoptosis via decreased expression of the anti-apoptotic protein survivin. These findings suggest the potential use of sunitinib for the treatment of poorly differentiated follicular thyroid carcinomas.
引用
收藏
页码:480 / 490
页数:11
相关论文
共 68 条
  • [41] Off-Label Use of Sunitinib in Patients with Advanced, Epithelial Thyroid Cancer: A Retrospective Analysis
    Pasqualetti, Giuseppe
    Ricci, Sergio
    Boni, Giuseppe
    Tognini, Sara
    Polini, Antonio
    Mariani, Giuliano
    Ferdeghini, Marco
    Monzani, Fabio
    [J]. RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2012, 6 (02) : 171 - 176
  • [42] SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
    Patyna, Shem
    Laird, A. Douglas
    Mendel, Dirk B.
    O'Farrell, Anne-Marie
    Liang, Chris
    Guan, Huiping
    Voikovsky, Tomas
    Vasile, Stefan
    Wang, Xueyan
    Chen, Jeffrey
    Grazzini, Maren
    Yang, Cheng Y.
    Haznedar, Joshua O.
    Sukbuntherng, Juthamas
    Zhong, Wei-Zhu
    Cherrington, Julie M.
    Hu-Lowe, Dana
    [J]. MOLECULAR CANCER THERAPEUTICS, 2006, 5 (07) : 1774 - 1782
  • [43] Activation of the RAS/RAF/ERK Signaling Pathway Contributes to Resistance to Sunitinib in Thyroid Carcinoma Cell Lines
    Piscazzi, Annamaria
    Costantino, Eleonora
    Maddalena, Francesca
    Natalicchio, Maria Iole
    Gerardi, Assunta Maria Teresa
    Antonetti, Raffaele
    Cignarelli, Mauro
    Landriscina, Matteo
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (06) : E898 - E906
  • [44] Pohl F, 2003, RADIAT RES, V159, P345, DOI 10.1667/0033-7587(2003)159[0345:RISOTB]2.0.CO
  • [45] 2
  • [46] Changes of Apoptosis, p53, and bcl-2 by Irradiation in Poorly Differentiated Thyroid Carcinoma Cell Lines: A Prognostic Marker for the Prospect of Therapeutic Success?
    Pohl, Fabian
    Grosse, Jirka
    Grimm, Daniela
    Brockhoff, Gero
    Westphal, Kriss
    Moosbauer, Jutta
    Koelbl, Oliver
    Infanger, Manfred
    Eilles, Christoph
    Schoenberger, Johann
    [J]. THYROID, 2010, 20 (02) : 159 - 166
  • [47] PREVOSTEL C, 1995, ONCOGENE, V11, P669
  • [48] Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer
    Rödel, F
    Hoffmann, J
    Distel, L
    Herrmann, M
    Noisternig, T
    Papadopoulos, T
    Sauer, R
    Rödel, C
    [J]. CANCER RESEARCH, 2005, 65 (11) : 4881 - 4887
  • [49] Complexities in the development of cyclin-dependent kinase inhibitor drugs
    Sausville, EA
    [J]. TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) : S32 - S37
  • [50] Innovative strategies in in vivo apoptosis imaging
    Schoenberger, Johann
    Bauer, Johann
    Moosbauer, Jutta
    Eilles, Christoph
    Grimm, Daniela
    [J]. CURRENT MEDICINAL CHEMISTRY, 2008, 15 (02) : 187 - 194